NEWS & EVENTS
The management of Ergomed (AIM:ERGO.L), which offers clinical trials and pharmacovigilance services to pharmaceutical companies, while also co-developing a product …READ MORE
The managers of Molins (AIM:MLIN), an international business providing high performance machinery and instrumentation, as well as services and support for …READ MORE
The management of Accrol Group Holdings plc (AIM:ACRL), a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues …READ MORE
All Blacks in blistering form in Sydney: 40-6 up v Aus by half time. Shows how well the Lions did to draw the series in NZ in the summer.
$PCA @Palace_Capital at all time high 390p on news today of major new planning application success in York.
$HCM Hutch Chi Med more Directors' buying: Chairman a buyer yesterday, post July's strong Interims. IPO'd at 275p 10 years ago, now 3700p
@DestinyPharma Britain can back world leading biotech: Destiny Pharma, developing vital new anti-bacterial drugs, intends to float on AIM.
$VAST.L @vast_resources Sub-Sahara matches $10m investment offer, keen to work with provider of first offer. Romanian assets clearly popular
US stocks remained subdued on White House paralysis, and Nikkei also fell 1.3% on weaker $. Expect UK shares to drift lower at open too.
WHY CHOOSE ED
"Many thanks to @equity_research for a superb Investor Forum. $BMK.L , $VLG.L & $VP.L all interesting companies. I recommend these events. "
"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."
"Thanks for working over the weekend on this – it is really appreciated, as always Benchmark gets massive benefit from ED’s work for us, and from your team’s wise counsel at these key moments."
"I thoroughly enjoyed the investor evening again, and as before its good that you get such an interested audience who engage and ask us all decent questions."